CliffBio
small molecule

RADICAVA

EDARAVONE

Loss of exclusivity—loss of exclusivity
CompanyShionogi →See this company's full patent-cliff portfolio

Drug detail

Brand nameRADICAVA
Active ingredientEDARAVONE
Strength60MG/100ML (0.6MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusDISCN

More from Shionogi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.